TG Therapeutics Inc. (TGTX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
TG Therapeutics Inc. (TGTX) receives a Roarable Rating of D (Sell) and flashes a Red SELL / AVOID warning (60/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+181.1% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
How TGTX Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $616.3M | 83.7% | 20% | $447.2M | -$25.0M | 12% |
| FY 2024 | $329.0M | 88.3% | 12.7% | $23.4M | -$40.6M | 11.5% |
| FY 2023 | $233.7M | 44% | 8.8% | $12.7M | -$41.9M | 0.6% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring TGTX)
- ✓Live walkthrough of TGTX's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
TGTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +87.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on TGTX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for TGTX. Explore sector supply chains on /butterfly.
TGTX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is TG Therapeutics Inc. (TGTX)?
In FY 2025 (10-K), TGTX converted $616.3M of revenue into a 83.7% gross margin, 20% operating margin, and $0 in free cash flow (0% FCF margin).